newsfilter
← Earnings
Earnings Releases·

Eloxx Pharmaceuticals — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Net loss for the three months ended September 30, 2026, was $5.5 million ($0.49 per share), compared to a net loss of $0.4 million ($0.58 per share) for the same period in 2025.
    • Net loss for the nine months ended September 30, 2026, was $13.8 million ($1.83 per share), compared to $4.0 million ($9.12 per share) for the same period in 2025.
    • Research and development (R&D) expenses were $4.0 million for the quarter ended September 30, 2026, compared to a net credit of $0.3 million for the same period in 2025; the increase was driven by higher clinical trial expenses for the Phase 2b EXACT study and personnel costs, while 2025 included a $0.9 million write-off of accounts payable.
    • General and administrative (G&A) expenses were $1.9 million for the quarter ended September 30, 2026, compared to $0.5 million for the same period in 2025, primarily due to higher professional fees, personnel costs, and overhead.
    • Other income, net, was $0.4 million for the quarter ended September 30, 2026, compared to other expense, net, of $0.1 million for the same period in 2025, driven by higher interest income following a June 2026 public offering.
    • Cash and cash equivalents were $56.3 million as of September 30, 2026, down from $62.0 million as of June 30, 2026.
    • Total assets were $58.3 million as of September 30, 2026, compared to $5.3 million as of December 31, 2025.
    • Total current liabilities were $17.2 million as of September 30, 2026, compared to $17.2 million as of December 31, 2025.
    • Total stockholders' equity was $41.1 million as of September 30, 2026, compared to a deficit of $11.9 million as of December 31, 2025.
    • A one-for-eleven reverse stock split was effected in May 2026; all share and per-share amounts reflect this adjustment.
  • Guidance and Future Outlook:

    • The Company expects to report topline data from the 16-week placebo-controlled portion of the Phase 2b EXACT study in mid-2027 and final 32-week data by the end of 2027.
    • The Company expects to dose the first patient in the Phase 2 EXPRESS study in the third quarter of 2027 and report 52-week topline data in the first half of 2029.
    • Management believes cash and cash equivalents will be sufficient to fund operations into 2028.
    • FDA feedback indicated that a substantial and durable effect on kidney volume growth, supported by kidney function and safety data, could be a potential basis for Breakthrough Therapy Designation, subject to clinical results and further review.
  • Business Segments and Product Lines:

    • The Company dosed the first two patients in the global Phase 2b EXACT study of exaluren for nonsense mutation Alport syndrome (NMAS) in September 2026; this is a randomized, placebo-controlled trial enrolling 24 patients.
    • The primary efficacy endpoint for the initial 16-week portion of the EXACT study is the change in podocyte foot process effacement (filtration slit density) in non-U.S. pediatric and all adult patients.
    • An earlier open-label Phase 2a study observed structural improvements, including reduced foot process effacement and improved glomerular basement membrane (GBM) width, in all three participants.
    • The Company finalized the protocol and received IND clearance for the Phase 2 EXPRESS study of exaluren in nonsense mutation autosomal dominant polycystic kidney disease (nmADPKD).
    • The EXPRESS study is a 52-week, global, randomized, placebo-controlled trial in approximately 60 adults with genetically confirmed nonsense mutations in PKD1 or PKD2 genes; the primary endpoint is the annualized rate of change in height-adjusted total kidney volume (htTKV).
    • Eloxx estimates 40,000 to 50,000 people in the United States have ADPKD caused by nonsense mutations.
    • The Company has exclusively licensed product candidate ZKN-013 to Almirall, S.A., for the treatment of rare dermatological diseases associated with nonsense mutations.
  • Market and Competitive Landscape:

    • The Company is developing exaluren, a small-molecule product candidate designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations.
    • The Company is focusing on rare kidney diseases, specifically nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD).
  • Risks and Challenges:

    • Forward-looking statements highlight risks including the need for and ability to obtain additional capital.
    • Risks include the uncertainty of timing, results, and expenses related to the clinical and regulatory development process.
    • Results from preclinical studies and early clinical trials are not necessarily predictive of future results.
    • The Company must maintain compliance with the continued listing requirements of the Nasdaq Capital Market.
  • Management Commentary and Tone:

    • Sumit Aggarwal, President and CEO, stated that the third quarter marked important progress with the dosing of the first two patients in the Phase 2b EXACT study and the receipt of IND clearance for the EXPRESS study.
    • Management noted the Company now has two programs in rare kidney disease.
    • The appointment of T.R. Srinivas, M.D., as SVP and Chief Medical Officer, reflects a focus on leading renal medical strategy across Alport syndrome and ADPKD programs.
  • Other Key Points:

    • T.R. Srinivas, M.D., was appointed Senior Vice President and Chief Medical Officer in October 2026, joining from Novartis where he held U.S. Medical Affairs leadership responsibilities for ADPKD product development.
    • Geno Germano was appointed to the Board of Directors in October 2026, bringing over 35 years of biopharmaceutical development and commercialization leadership, including prior roles as CEO of Elucida Oncology, President of Intrexon, and Group President of Pfizer's Global Innovative Pharmaceutical business.
    • The Company completed a public offering in June 2026, which contributed to increased cash balances and interest income.
    • The Phase 2b EXACT study (NCT07523581) targets patients with nonsense mutations in the COL4A3, COL4A4, or COL4A5 genes.
    • The Phase 2 EXPRESS study design was finalized to randomize patients 1:1 to receive exaluren or placebo.
Company
ELOXX PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology